PET amyloid-beta imaging in preclinical Alzheimer's disease - Wikidata - wikimedia - TriplyDB

PET amyloid-beta imaging in preclinical Alzheimer's disease

PET amyloid-beta imaging in preclinical Alzheimer's disease

http://www.wikidata.org/entity/Q30040695

about

Advances in MRI biomarkers for the diagnosis of Alzheimer's disease.Identification of Differentially Expressed Genes through Integrated Study of Alzheimer's Disease Affected Brain Regions Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?What amyloid ligands can tell us about molecular polymorphism and disease.Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2.Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.Dementia risk and prevention by targeting modifiable vascular risk factors.Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.Attitudes to Alzheimer's disease testing of Australian general practice patients: a cross-sectional questionnaire-based study.Proenergetic effects of resveratrol in the murine neuronal cell line Neuro2a.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease.FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E ɛ4 Carriers.Spectroscopic imaging with spectral domain visible light optical coherence microscopy in Alzheimer's disease brain samples.Design, synthesis and biological evaluation of trimethine cyanine dyes as fluorescent probes for the detection of tau fibrils in Alzheimer's disease brain and olfactory epithelium.Pittsburgh Compound-B (PiB) binds amyloid β-protein protofibrils.In vivo staging of regional amyloid deposition.Taming Alzheimer's disease: New perspectives, newer horizons.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Novel Cognitive Paradigms for the Detection of Memory Impairment in Preclinical Alzheimer's Disease.An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.Diffusion kurtosis imaging to detect amyloidosis in an APP/PS1 mouse model for Alzheimer's disease.Mixed dementia: A review of the evidence.Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.Regional association of pCASL-MRI with FDG-PET and PiB-PET in people at risk for autosomal dominant Alzheimer's disease.Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.Amyloid pathology fingerprint differentiates post-traumatic stress disorder and traumatic brain injury.F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease The Binding of BF-227-Like Benzoxazoles to Human α-Synuclein and Amyloid β Peptide Fibrils Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer's disease

P2860

Q30870223-045931A4-2080-49B1-9916-0A5D2BEBC9E6 Q35981049-18DB19A4-6F6C-4718-AA57-E36D4007150E Q36218847-8F0172CA-43A8-4440-84F3-C19C5D2C44BA Q36711795-35BD8C37-7A61-4EB5-AE3A-0494FBE94B96 Q36871202-056CBE49-B87C-42DC-8053-0718D41D3ED0 Q37108643-F867FEDA-1F08-44AB-8694-507DACCB0755 Q37111515-84864E86-019C-4C9F-8024-ED69056E9952 Q37348968-E1DE296A-6A41-4A77-B2D1-CB46915808E5 Q38113683-71674416-5F46-44E3-A6EC-09AB625C9E67 Q38653373-FC6AD231-9C05-4C37-9AFB-F2C560A0007F Q38831113-8ECEC3B0-32D3-4BF8-89D5-5D96C90050B6 Q38975863-E976B6C2-919B-4B3C-A4FC-91CF6D8AA827 Q39112076-0D7494DA-738A-4FD5-A6A2-8DD1A12EF937 Q39217840-5107717E-0887-4141-AC13-97FCB2B787F4 Q39558338-ECC70E8A-B51B-40F3-83FF-DB5432C24507 Q39775642-ABEAB885-9048-4456-B21E-CEF9A13DEFF6 Q39810517-64B62CDA-D6D2-43B8-A7A4-23F493ECB74B Q41997192-E9B750B2-5E44-4DCC-93EA-434474661E4E Q44143296-8FA7996B-2083-41FF-B944-886C0F8BD86E Q46612446-49D7C4D2-06F2-4532-B5D7-A66DD26E287D Q47123732-8281DB7B-12A0-4CD0-B849-AA8D66512CF8 Q47171672-24F9BF2A-6A19-471B-ACA9-CEE29C781363 Q47587631-85281276-0DEE-4FAF-A556-080AEA4780E7 Q47795787-E8622283-4D1E-4675-A4B8-AD4E12005D1C Q47967419-14B6A385-8A00-4AE0-B6F7-B128D9B9794A Q48125155-11CF2E0B-14B2-4642-B3FD-69A5574BD545 Q48514781-2B649769-9203-42C6-BCD8-77A0B02826E8 Q48609636-F1C61B0A-517B-4935-B4AA-2F2B49132254 Q53396334-AC212156-24E7-458A-AAB0-CD1A4DB049F3 Q55353865-16209992-E38D-49DF-82F3-DB450911E771 Q55632590-C178B606-171E-4884-AE0B-34079F946754 Q58733228-ED3CBDE9-1302-4875-8AD8-0521083649E2 Q58740165-C497895B-9E80-4A91-BAB0-0DB40D314F29 Q58740989-6FDD86B3-CBD5-4D29-9BF4-56C35CC73E6B

P2860

PET amyloid-beta imaging in preclinical Alzheimer's disease

http://www.wikidata.org/entity/Q30040695

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

PET amyloid-beta imaging in preclinical Alzheimer's disease

@ast

PET amyloid-beta imaging in preclinical Alzheimer's disease

@en

type

label

PET amyloid-beta imaging in preclinical Alzheimer's disease

@ast

PET amyloid-beta imaging in preclinical Alzheimer's disease

@en

prefLabel

PET amyloid-beta imaging in preclinical Alzheimer's disease

@ast

PET amyloid-beta imaging in preclinical Alzheimer's disease

@en

P1433

Q30040695-FF1E594E-D72F-427B-9204-DCBC2CD1DD5F

P1476

Q30040695-60EBEA32-3789-4DC2-ABC3-4846F5CAA192

P2093

Q30040695-1249AFFC-8AB2-4A21-9D3E-38A771B7AA49

Q30040695-1A6888D8-341B-4BDC-BE97-CB8F0850E1E2

Q30040695-5E19EFB5-FCA6-4586-8A14-F0A54EE5DD8B

P2860

Q30040695-002A23AE-C87E-4DCF-BAD2-3374941BB3A3

Q30040695-00765FF0-2301-4E9D-88BD-D559286BAD29

Q30040695-007E91FA-AE71-43EC-843A-90C585686677

Q30040695-01D38848-BF43-4641-8896-F29EAE04B791

Q30040695-020BAFF6-7C42-48A0-B3E9-F1DF8B2FDFF2

Q30040695-048CC7C6-56B9-494C-B2B1-20B5B2C88A5F

Q30040695-06484D1A-84FF-4400-ACC4-0572CED5D747

Q30040695-0696DFCA-D36C-4DAB-A328-ECF1ED38AE78

Q30040695-07B8F020-B7C2-4D4F-836D-2E0D86BC3465

Q30040695-07D7A40C-254B-4667-A1D3-C4CB99C821AF

P304

Q30040695-7434851E-C410-4470-AC04-FCDB5E0A6E89

P31

Q30040695-CC173CB2-F9DC-48E7-8BAD-DA6B042DACD9

P3181

Q30040695-7E8FC63E-82F6-49FC-82BD-3367D6F524CF

P356

Q30040695-1A7E8495-CF8F-4DAA-A431-D2A8524183CF

P433

Q30040695-9268FDDB-4345-4C77-B505-DE255FC29D6F

P478

Q30040695-F87CD780-64A0-4428-82B8-E86AE12C1597

P577

Q30040695-77736FC7-9148-4CEA-9194-6E91705A2D3B

P5875

Q30040695-406A029A-135E-4C80-9268-DC604169DFA3

P698

Q30040695-3164ACB2-4B20-4A25-AB09-2350CC2EFB01

P921

Q30040695-DEA33F19-079F-4E49-99A6-A905B4D85756

P932

Q30040695-179AEEAB-6C1B-4525-9C4E-06F7B97649AA

P3181

P356

J.BBADIS.2011.11.005

P1433

BBA: Molecular Basis of Disease

P1476

PET amyloid-beta imaging in preclinical Alzheimer's disease

@en

P2093

Andrei G. Vlassenko

http://www.w3.org/2001/XMLSchema#string

John C. Morris

http://www.w3.org/2001/XMLSchema#string

Tammie L.S. Benzinger

http://www.w3.org/2001/XMLSchema#string

P2860

Cognitive Reserve and Alzheimer Disease

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Alzheimer Disease in the US Population

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition

Regional aerobic glycolysis in the human brain

Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly

P304

370-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2124314

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BBADIS.2011.11.005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1822

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51821823

http://www.w3.org/2001/XMLSchema#string

P698

22108203

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

3264790

http://www.w3.org/2001/XMLSchema#string